Research: Gonococcal Resistance to Antimicrobials Surveillance Programme report

Download the GRASP 2024 slide set for presentational use.

Surveillance of antimicrobial resistance is critical in guiding national treatment guidelines to ensure appropriate patient management. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) includes a suite of testing and surveillance systems to detect and monitor antimicrobial resistance in Neisseria (N.) gonorrhoeae and potential treatment failures.

The UK Health Security Agency (UKHSA) reports annually on drug resistance and decreased susceptibility in N. gonorrhoeae in England and Wales and has directly influenced changes in treatment guidelines on 3 occasions. The national gonorrhoea management guideline was updated by the British Association for Sexual Health and HIV (BASHH) in April 2025.

Information on suspected gonorrhoea treatment failures should be reported to UKHSA via the HIV and STI Data Exchange. This has restricted access for authorised users only.

Disseminated gonococcal infection (DGI) is a notifiable disease in England as of April 2025. UKHSA performs enhanced surveillance of DGI. Upon notification, UKHSA will ask reporters to complete an enhanced surveillance questionnaire. Please contact [email protected] (no Personal Identifiable Information (PII)) if advice on case management is needed.